{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:57:15Z","timestamp":1789811835556,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gut Pathog"],"DOI":"10.1186\/s13099-026-00802-y","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T09:04:58Z","timestamp":1770541498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical impact of high-dose esomeprazole-amoxicillin dual therapy as rescue treatment for Helicobacter pylori infection: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Iftikhar","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ansab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooria Aiman","family":"Shadab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Sawaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6830-4529","authenticated-orcid":false,"given":"Ehsanullah","family":"Alokozay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Naseer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Fawzi","family":"Hemida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor Asghar","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soban Ali","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Amanullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"issue":"2","key":"802_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.022.","journal-title":"Gastroenterology"},{"issue":"4","key":"802_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/CMR.00011-10","volume":"23","author":"LE Wroblewski","year":"2010","unstructured":"Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23(4):713\u201339. https:\/\/doi.org\/10.1128\/CMR.00011-10.","journal-title":"Clin Microbiol Rev"},{"key":"802_CR3","first-page":"1","volume":"61","author":"Schistosomes","year":"1994","unstructured":"Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1\u2013241. PMID: 7715068; PMCID: PMC7681621.","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"issue":"7","key":"802_CR4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/apt.14561","volume":"47","author":"M Zamani","year":"2018","unstructured":"Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868\u201376. https:\/\/doi.org\/10.1111\/apt.14561.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"802_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report. Gut. 2017;66(1):6\u201330. https:\/\/doi.org\/10.1136\/gutjnl-2016-312288.","journal-title":"Gut"},{"issue":"4","key":"802_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/apt.13497","volume":"43","author":"I Thung","year":"2016","unstructured":"Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514\u201333. https:\/\/doi.org\/10.1111\/apt.13497.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"802_CR7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","volume":"155","author":"A Savoldi","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-1382.e17. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.007.","journal-title":"Gastroenterology"},{"issue":"2","key":"802_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41395-018-0132-6","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212\u201339. https:\/\/doi.org\/10.1038\/s41395-018-0132-6.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"802_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/gutjnl-2021-325630","volume":"71","author":"SZ Ding","year":"2022","unstructured":"Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, et al. Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 Edition). Gut. 2022;71(2):238\u201353. https:\/\/doi.org\/10.1136\/gutjnl-2021-325630.","journal-title":"Gut"},{"issue":"10","key":"802_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/MEG.0b013e3283633b57","volume":"25","author":"H Lu","year":"2013","unstructured":"Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol. 2013;25(10):1134\u201340. https:\/\/doi.org\/10.1097\/MEG.0b013e3283633b57.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"802_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cgh.2014.10.036","volume":"13","author":"JC Yang","year":"2015","unstructured":"Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895-905.e5. https:\/\/doi.org\/10.1016\/j.cgh.2014.10.036.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"802_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/1751-2980.12034","volume":"14","author":"WZ Liu","year":"2013","unstructured":"Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori, Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, et al. Fourth Chinese National consensus report on the management of Helicobacter pylori infection. J Dig Dis. 2013;14(5):211\u201321. https:\/\/doi.org\/10.1111\/1751-2980.12034.","journal-title":"J Dig Dis"},{"issue":"12","key":"802_CR13","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.4103\/jfmpc.jfmpc_1035_22","volume":"11","author":"E Hajiani","year":"2022","unstructured":"Hajiani E, Hashemi SJ, Parsi A, Seyedian SS, Ramim T, Sabbaghan A. Eradication efficacy of high-dose amoxicillin and proton pump inhibitor compared with quadruple therapy contained bismuth in the treatment of Helicobacter pylori. J Fam Med Prim Care. 2022;11(12):7806\u20139. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1035_22.","journal-title":"J Fam Med Prim Care"},{"issue":"6","key":"802_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"JM Shin","year":"2008","unstructured":"Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528\u201334. https:\/\/doi.org\/10.1007\/s11894-008-0098-4.","journal-title":"Curr Gastroenterol Rep"},{"key":"802_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002100","author":"C Wang","year":"2024","unstructured":"Wang C, Wang HJ, Li K, Wang Y, Lin YY, Weng CZ, et al. Clinical impact of high-dose esomeprazole-amoxicillin dual therapy as rescue treatment for Helicobacter pylori infection\u202f: a prospective, multicenter, randomized trial. J Clin Gastroenterol. 2024. https:\/\/doi.org\/10.1097\/MCG.0000000000002100.","journal-title":"J Clin Gastroenterol"},{"issue":"14","key":"802_CR16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/CM9.0000000000002289","volume":"135","author":"H Bi","year":"2022","unstructured":"Bi H, Chen X, Chen Y, Zhao X, Wang S, Wang J, et al. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. Chin Med J (Engl). 2022;135(14):1707\u201315. https:\/\/doi.org\/10.1097\/CM9.0000000000002289.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"802_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/jac\/dkad020","volume":"78","author":"ZH Ding","year":"2023","unstructured":"Ding ZH, Huang Y, Chen JN, Luo LS, Zhang W, Liang X, et al. A randomized superiority clinical trial: metronidazole improved the efficacy of high-dose dual therapy in Helicobacter pylori rescue treatment. J Antimicrob Chemother. 2023;78(3):828\u201331. https:\/\/doi.org\/10.1093\/jac\/dkad020.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"802_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608\u201319. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055.","journal-title":"Gastroenterology"},{"key":"802_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"802_CR20","unstructured":"PROSPERO [Internet]. [cited 2025 May 3]. Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/home"},{"key":"802_CR21","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019;366. Available from: https:\/\/www.bmj.com\/content\/366\/bmj.l4898 https:\/\/www.bmj.com\/content\/366\/bmj.l4898.abstract","DOI":"10.1136\/bmj.l4898"},{"key":"802_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","volume":"74","author":"N Antesso","year":"2016","unstructured":"Antesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P, et al. Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and Understanding GRADE certainty in the evidence judgments. J Clin Epidemiol. 2016;74:28\u201339.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"802_CR23","first-page":"195","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16(4):195.","journal-title":"JBI Evid Implement"},{"key":"802_CR24","doi-asserted-by":"crossref","unstructured":"Mladenova I. Epidemiology of Helicobacter pylori Resistance to Antibiotics (A Narrative Review). Antibiotics [Internet]. 2023;12(7):1184. Available from: https:\/\/www.mdpi.com\/2079-6382\/12\/7\/1184","DOI":"10.3390\/antibiotics12071184"},{"key":"802_CR25","doi-asserted-by":"crossref","unstructured":"Taufiq M, Taufiq M. Current Perspective on the Treatment of Helicobacter pylori Infection. In: IntechOpen eBooks [Internet]. 2024. Available from: https:\/\/www.intechopen.com\/chapters\/88850","DOI":"10.5772\/intechopen.114135"},{"key":"802_CR26","doi-asserted-by":"crossref","unstructured":"Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol [Internet]. 2017 [cited 2025 May29];29(5):552\u20139. Available from: https:\/\/journals.lww.com\/eurojgh\/fulltext\/2017\/05000\/the_irish_helicobacter_pylori_working_group.10.aspx","DOI":"10.1097\/MEG.0000000000000822"},{"key":"802_CR27","doi-asserted-by":"crossref","unstructured":"Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology [Internet]. 2016 Jul 1 [cited 2025 May 29];151(1):51\u201369.e14. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0016508516301081","DOI":"10.1053\/j.gastro.2016.04.006"},{"key":"802_CR28","doi-asserted-by":"crossref","unstructured":"Gao W, Cheng H, Hu F, Li J, Wang L, Yang G et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter [Internet]. 2010 Oct [cited 2025 May 29];15(5):460\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21083752\/","DOI":"10.1111\/j.1523-5378.2010.00788.x"},{"key":"802_CR29","doi-asserted-by":"crossref","unstructured":"Wang SW, Yu FJ, Kuo FC, Wang JW, Wang YK, Chen YH et al. Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts. Therap Adv Gastroenterol [Internet]. 2023 Jan 1 [cited 2025 May 29];16:17562848231170940. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10164852\/","DOI":"10.1177\/17562848231170941"},{"key":"802_CR30","unstructured":"Chunlertlith K, Limpapanasit U, Mairiang P, Vannaprasaht S, Tassaneeyakul W, Sangchan A et al. Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication. Asian Pacific Journal of Cancer Prevention [Internet]. 2017 Apr 1 [cited 2025 May 29];18(4):927\u201332. Available from: https:\/\/journal.waocp.org\/article_45887.html"},{"key":"802_CR31","doi-asserted-by":"crossref","unstructured":"Sjomina O, Lielause A, R\u016bdule A, Vangravs R, Par\u0161utins S, Po\u013caka I et al. Randomised clinical trial: Comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication. European Journal of Cancer Prevention [Internet]. 2022 Jul 1 [cited 2025 May 29];31(4):333\u20138. Available from: https:\/\/journals.lww.com\/eurjcancerprev\/fulltext\/2022\/07000\/randomised_clinical_trial__comparison_of_efficacy.4.aspx","DOI":"10.1097\/CEJ.0000000000000718"},{"issue":"5","key":"802_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(24)01469-0","volume":"166","author":"PI Hsu","year":"2024","unstructured":"Hsu PI, Shih CA, Chen CL, Chuah SK, Yang JC, Wu DC. Sa1367 both 14-day vonoprazan triple therapy and 14-day rabeprazole reverse hybrid therapy are superior to 14-day vonoprazan high-dose dual therapy for the first-line anti-H. pylori treatment in population with high rates of antibiotic resistance. Gastroenterology. 2024;166(5):S-431.","journal-title":"Gastroenterology"},{"key":"802_CR33","unstructured":"Hafeez M, Qureshi ZA, Khattak AL, Saeed F, Asghar A, Azam K et al. Helicobacter Pylori Eradication Therapy: Still a Challenge. Cureus [Internet]. 2021 May 6 [cited 2025 May 29];13(5):e14872. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8184113\/"},{"issue":"6","key":"802_CR34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.5152\/tjg.2022.21579","volume":"33","author":"Z Yin","year":"2022","unstructured":"Yin Z, Li J, Huang W, Lei X, Xu D, Xu G, et al. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Turk J Gastroenterol. 2022;33(6):454\u201362. https:\/\/doi.org\/10.5152\/tjg.2022.21579.","journal-title":"Turk J Gastroenterol"},{"key":"802_CR35","doi-asserted-by":"crossref","unstructured":"Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter [Internet]. 2020 Aug 1 [cited 2025 May 29];25(4). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32314468\/","DOI":"10.1111\/hel.12692"},{"key":"802_CR36","doi-asserted-by":"crossref","unstructured":"Phan NT, Truong LH. Effectiveness of 14-day high-dose dual therapy for Helicobacter pylori infection in Vietnam. J Infect Dev Ctries [Internet]. 2025 [cited 2025 May 29];19(3):404\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40168383\/","DOI":"10.3855\/jidc.20820"},{"issue":"4","key":"802_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","volume":"12","author":"DY Graham","year":"2007","unstructured":"Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275\u20138. https:\/\/doi.org\/10.1111\/j.1523-5378.2007.00518.x.","journal-title":"Helicobacter"},{"issue":"9862","key":"802_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","volume":"381","author":"JM Liou","year":"2013","unstructured":"Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet (London, England). 2013;381(9862):205\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(12)61579-7.","journal-title":"Lancet (London, England)"},{"key":"802_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221147756","volume":"16","author":"BG Zhou","year":"2023","unstructured":"Zhou BG, Mei YZ, Zhang M, Jiang X, Li YY, Ding YB. High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Therapeutic Advances in Gastroenterology. 2023;16:17562848221147756. https:\/\/doi.org\/10.1177\/17562848221147756.","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"5","key":"802_CR40","first-page":"593","volume":"9","author":"OP Nyssen","year":"2021","unstructured":"Nyssen OP, McNicholl AG, Rodrigo L, et al. Helicobacter pylori first-line treatment and rescue options in europe: results from the European registry on H. pylori management (Hp-EuReg). United Eur Gastroenterol J. 2021;9(5):593\u2013603.","journal-title":"United Eur Gastroenterol J"},{"key":"802_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221142925","author":"H Mei","year":"2022","unstructured":"Mei H, Guo Y, Zhao J-T, et al. Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial. Therap Adv Gastroenterol. 2022. https:\/\/doi.org\/10.1177\/17562848221142925.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"802_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/phar.2662","volume":"42","author":"JL Guan","year":"2022","unstructured":"Guan JL, Hu YL, An P, He Q, Long H, Zhou L, et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial. Pharmacotherapy. 2022;42(3):224\u201332. https:\/\/doi.org\/10.1002\/phar.2662.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"802_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12596","volume":"24","author":"L Yu","year":"2019","unstructured":"Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, et al. High\u2010dose ppi\u2010amoxicillin dual therapy with or without bismuth for first\u2010line Helicobacter pylori therapy: a randomized trial. Helicobacter. 2019;24(4):e12596. https:\/\/doi.org\/10.1111\/hel.12596.","journal-title":"Helicobacter"}],"container-title":["Gut Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13099-026-00802-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-026-00802-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-026-00802-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:48:46Z","timestamp":1780019326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13099-026-00802-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1186\/s13099-026-00802-y","relation":{},"ISSN":["1757-4749"],"issn-type":[{"value":"1757-4749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,8]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflicts of interest relevant to this manuscript. The authors received no financial support or funding for conducting or preparing this study. All authors have read and approved the revised manuscript and agree to be accountable for its contents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"44"}}